BWMG
ALNY icon

Bannerman Wealth Management Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bannerman Wealth Management Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$567K Sell
1,883
-33
-2% -$9.95K 0.33% 23
2026
Q1 		$634K Sell
1,916
-31
-2% -$10.5K 0.43% 21
2025
Q4 		$774K Sell
1,947
-100
-5% -$44.3K 0.55% 18
2025
Q3 		$933K Sell
2,047
-117
-5% -$47.6K 0.69% 17
2025
Q2 		$706K Sell
2,164
-565
-21% -$156K 0.54% 20
2025
Q1 		$737K Buy
2,729
+1,338
+96% +$344K 0.6% 17
2024
Q4 		$327K Buy
+1,391
New +$366K 0.27% 23

Other funds holding ALNY

Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bannerman Wealth Management Group's ALNY Position: Q2 2026 in Review

Bannerman Wealth Management Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.7% in Q2 2026, selling an estimated $9.95K and leaving 1,883 shares worth $567K. The position accounts for 0.33% of the portfolio, ranked #23.

Bannerman Wealth Management Group first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $933K in Q3 2025. 259 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bannerman Wealth Management Group held 1,883 shares of Alnylam Pharmaceuticals worth $567K as of Q2 2026.
  • Bannerman Wealth Management Group sold 33 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.95K.
  • Alnylam Pharmaceuticals made up 0.33% of Bannerman Wealth Management Group's portfolio in Q2 2026, its #23 holding.
  • Bannerman Wealth Management Group first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Bannerman Wealth Management Group's Alnylam Pharmaceuticals position peaked at $933K in Q3 2025.
  • 259 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bannerman Wealth Management Group's 13F filing for Q2 2026, filed 8 Jul 2026.